KalshiGeslotenBeschikbaarheid controlerenKYC vereist2% kostenGeverifieerde afwikkelingsgegevensRedelijk gekalibreerdDeze markt is gesloten en wacht op bevestigde afwikkeling.
Wacht op geverifieerde afwikkeling
CoinRithm wacht op door de provider bevestigde afwikkeling voordat deze markt als beslist wordt behandeld.
Huidige impliciete kans
Before 2027 35%Koploper van 3 uitkomsten
Marktkwaliteit
35 / 100
Lage kwaliteit24u volume
—
Liquiditeit
€ 29,7K
Hoge liquiditeitMarktdata
Bijgewerkt 12 minuten geleden
24 mrt 26, 14:00 UTC1 sep 26, 03:59 UTC
Trends
35%
20%
2%
Gerelateerde Markten
Gerelateerde vragen voor context, geen vergelijking van gelijkwaardige contracten.
FDA moves BPC-157 to Category 1 by which date?
PolymarketHantavirus pandemic in 2026?
PolymarketWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
KalshiWill we get AGI before 2027?
Manifold MarketsFDA approves skin cancer vaccine by which date?
PolymarketMeasles cases in 2026?
KalshiRegels
If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.
Afwikkeling via:Food and Drug Administration
- The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility.
- Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Nov 1, 2026, then the market resolves to Yes.
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jan 1, 2027, then the market resolves to Yes.
Open markten
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No97%
- Yes3%
- Totaal volume
- € 15,6 mln.
- 24u volume
- € 18K
POLYMARKETNew pandemic in 2026?
- No94.1%
- Yes5.9%
- Totaal volume
- € 920,1K
- 24u volume
- € 4K
KALSHIMedtronic cardiovascular growth in Q2
- Above 8%92%
- Above 9%81%
- Above 11.5%53%
+6 extra uitkomsten
- Totaal volume
- € 2,6K
- 24u volume
- € 2,6K
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 4000+1.0pt98%
- Above 6000+2.0pt61%
+2 extra uitkomsten
- Totaal volume
- € 868,1K
POLYMARKETMeasles cases in U.S. in 2026?
- ↑3.5k100%
- ↑500+0.1pt100%
- ↑1k+0.1pt100%
+9 extra uitkomsten
KALSHIPandemic in 2026?
- No95%
- Yes5%
- Totaal volume
- € 612,7K
- 24u volume
- € 1,2K
- When will Beam Therapeutics submit a BLA for Risto-cel?
- Which countries will report an Ebola disease case before October?
- What will RFK say during RNC Midterm Convention?
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Will the FDA approve retatrutide?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- Measles cases in U.S. by September 30?
- Will WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- How many West Nile neuroinvasive disease cases will be reported among New York City residents in 2026?
Veelgestelde vragen
- Wat zijn de huidige kansen voor When will the FDA reclassify BPC-157 to Category 1??
- Kalshi prijst Before 2027 op 35% per 10 september 2026.
- Wanneer wordt When will the FDA reclassify BPC-157 to Category 1? afgewikkeld?
- When will the FDA reclassify BPC-157 to Category 1? wordt naar verwachting op 1 september 2026 afgewikkeld.
- Hoe wordt When will the FDA reclassify BPC-157 to Category 1? afgewikkeld?
- Kalshi wikkelt deze markt als volgt af: If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.